- Home
- JOF vs MNPR Comparison
JOF vs MNPR Comparison
Compare JOF & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOF
- MNPR
- Stock Information
- Founded
- JOF 1990
- MNPR 2014
- Country
- JOF Japan
- MNPR United States
- Employees
- JOF N/A
- MNPR N/A
- Industry
- JOF Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- JOF Finance
- MNPR Health Care
- Exchange
- JOF Nasdaq
- MNPR Nasdaq
- Market Cap
- JOF 295.5M
- MNPR 248.8M
- IPO Year
- JOF N/A
- MNPR 2019
- Fundamental
- Price
- JOF $10.49
- MNPR $32.06
- Analyst Decision
- JOF
- MNPR Strong Buy
- Analyst Count
- JOF 0
- MNPR 7
- Target Price
- JOF N/A
- MNPR $62.00
- AVG Volume (30 Days)
- JOF 43.9K
- MNPR 29.7K
- Earning Date
- JOF 01-01-0001
- MNPR 08-12-2025
- Dividend Yield
- JOF 3.33%
- MNPR N/A
- EPS Growth
- JOF N/A
- MNPR N/A
- EPS
- JOF N/A
- MNPR N/A
- Revenue
- JOF N/A
- MNPR N/A
- Revenue This Year
- JOF N/A
- MNPR N/A
- Revenue Next Year
- JOF N/A
- MNPR N/A
- P/E Ratio
- JOF N/A
- MNPR N/A
- Revenue Growth
- JOF N/A
- MNPR N/A
- 52 Week Low
- JOF $6.64
- MNPR $2.25
- 52 Week High
- JOF $8.04
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- JOF 65.95
- MNPR 37.84
- Support Level
- JOF $10.30
- MNPR $30.51
- Resistance Level
- JOF $10.55
- MNPR $37.56
- Average True Range (ATR)
- JOF 0.16
- MNPR 3.38
- MACD
- JOF 0.00
- MNPR -0.69
- Stochastic Oscillator
- JOF 83.77
- MNPR 12.93
About JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.